Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 6/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2677278 | 0.79 | RAB9A (0.39) | FAAHCHRNA7HTR3ACHRNB4CHRNA3 | |
| SCHEMBL2677215 | 0.78 | CHRNA7 (0.47) | KCNH2CHRNA7HTR3ACHRNB4CHRNA3 | |
| SCHEMBL2676493 | 0.78 | NPC1 (0.62) | CHRNA7HTR3ACHRNB4CHRNA3NPC1 | |
| SCHEMBL2676639 | 0.77 | CHRNA7 (0.64) | CHRNA7HTR3ACHRNB4CHRNA3 | |
| SCHEMBL1449712 | 0.76 | CHRNA7 (0.47) | KCNH2CHRNA7HTR3ACHRNB4CHRNA3 | |
| SCHEMBL2677280 | 0.76 | CNR2 (0.61) | FAAHCHRNA7HTR3ACHRNB4CHRNA3 | |
| SCHEMBL1449914 | 0.75 | NPC1 (0.62) | CHRNA7HTR3ACHRNB4CHRNA3NPC1 | |
| SCHEMBL1449402 | 0.74 | CHRNA7 (0.64) | CHRNA7HTR3ACHRNB4CHRNA3 | |
| SCHEMBL5832693 | 0.74 | KDM1A (0.47) | FAAHKDM1ACHRM2CHRM4CHRM5 | |
| SCHEMBL1449396 | 0.73 | CNR2 (0.61) | FAAHCHRNA7HTR3ACHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173658-B2 | Diagnosis test; mixing blood or other fluid sample with test compound; analyzing, calibration; central nervous system disorders; analgesics; antiinflamamtory agents; drug abuse; anxiolytic agents; cognition activators;Alzheimer's disease; Parkinson's disease; Huntington's disease; hyperactivity | NEUROSEARCH A/S (DK) | 2012-05-08 | — | — | US | claimed |
| EP-2246352-A1 | Novel diazabicyclic aryl derivatives and their medical use | NeuroSearch AS (DK) | 2010-11-03 | — | — | EP | claimed |
| US-20080280912-A1 | Diagnosis test; mixing blood or other fluid sample with test compound; analyzing, calibration; central nervous system disorders; analgesics; antiinflamamtory agents; drug abuse; anxiolytic agents; cognition activators;Alzheimer's disease; Parkinson's disease; Huntington's disease; hyperactivity | NEUROSEARCH A/S | 2008-11-13 | — | — | US | claimed |
| US-8173658-B2 | Diagnosis test; mixing blood or other fluid sample with test compound; analyzing, calibration; central nervous system disorders; analgesics; antiinflamamtory agents; drug abuse; anxiolytic agents; cognition activators;Alzheimer's disease; Parkinson's disease; Huntington's disease; hyperactivity | NEUROSEARCH A/S (DK) | 2012-05-08 | — | — | US | disclosed |
| EP-2246352-A1 | Novel diazabicyclic aryl derivatives and their medical use | NeuroSearch AS (DK) | 2010-11-03 | — | — | EP | disclosed |
| US-20080280912-A1 | Diagnosis test; mixing blood or other fluid sample with test compound; analyzing, calibration; central nervous system disorders; analgesics; antiinflamamtory agents; drug abuse; anxiolytic agents; cognition activators;Alzheimer's disease; Parkinson's disease; Huntington's disease; hyperactivity | NEUROSEARCH A/S | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280912-A1 | Diagnosis test; mixing blood or other fluid sample with test compound; analyzing, calibration; central nervous system disorders; analgesics; antiinflamamtory agents; drug abuse; anxiolytic agents; cognition activators;Alzheimer's disease; Parkinson's disease; Huntington's disease; hyperactivity | ACHE, CHRNA6, CHRNA10 | KCNH2 1859/4885FAAH 560/4885CHRNA7 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.